Halozyme Therapeutics, Inc. Analyst EPS Estimates
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2024 | 3 | $0.69 | $0.69 | $0.69 |
| Q2 2024 | 3 | $0.74 | $0.74 | $0.74 |
| Q3 2024 | 2 | $0.94 | $0.98 | $0.96 |
| Q4 2024 | 6 | $1.06 | $1.29 | $1.19 |
| Q1 2025 | 3 | $0.98 | $1.05 | $1.02 |
| Q2 2025 | 2 | $1.07 | $1.18 | $1.12 |
| Q3 2025 | 2 | $1.12 | $1.24 | $1.17 |
| Q4 2025 | 2 | $1.22 | $1.35 | $1.28 |
Halozyme Therapeutics, Inc. Earnings Date And Information
Halozyme Therapeutics, Inc. last posted its earnings results on Thursday, October 31st, 2024. The company reported $1.27 earnings per share for the quarter, topping analysts' consensus estimates of $0.98 by $0.29. The company had revenue of 290.08 M for the quarter and had revenue of 829.25 M for the year. Halozyme Therapeutics, Inc. has generated $2 earnings per share over the last year ($2.1 diluted earnings per share) and currently has a price-to-earnings ratio of 18.73. Halozyme Therapeutics, Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, February 18th, 2025 based on prior year's report dates.
Halozyme Therapeutics, Inc. Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 10/31/2024 | Q3 2024 | $0.98 | $1.08 | 0.1 | $252.17 M | $290.08 M |
| 08/06/2024 | Q2 2024 | $0.76 | $0.73 | -0.03 | $204.94 M | $231.35 M |
| 05/07/2024 | Q1 2024 | $0.70 | $0.61 | -0.09 | $195.88 M | |
| 02/20/2024 | Q4 2023 | $0.82 | $0.66 | -0.16 | $230.04 M | |
| 11/06/2023 | Q3 2023 | $0.71 | $0.62 | -0.09 | $216.08 M | $216.03 M |
| 08/08/2023 | Q2 2023 | $0.63 | $0.57 | -0.06 | $199.95 M | $221.04 M |
| 05/09/2023 | Q1 2023 | $0.48 | $0.29 | -0.19 | $162.14 M | |
| 02/21/2023 | Q4 2022 | $0.47 | $0.43 | -0.04 | $181.50 M | |
| 11/08/2022 | Q3 2022 | $0.52 | $0.45 | -0.07 | $191.17 M | $208.98 M |
| 08/09/2022 | Q2 2022 | $0.50 | $0.16 | -0.34 | $138.63 M | $152.37 M |
| 05/10/2022 | Q1 2022 | $0.49 | $0.44 | -0.05 | $117.28 M | |
| 02/22/2022 | Q4 2021 | $0.41 | $0.48 | 0.07 | $102.00 M | |
| 11/02/2021 | Q3 2021 | $0.42 | $1.53 | 1.11 | $105.84 M | $115.83 M |
| 08/09/2021 | Q2 2021 | $0.41 | $0.64 | 0.23 | $104.12 M | $136.46 M |
| 05/10/2021 | Q1 2021 | $0.31 | $0.20 | -0.11 | $89.02 M | |
| 02/23/2021 | Q4 2020 | $0.53 | $0.54 | 0.01 | $121.70 M | |
| 11/02/2020 | Q3 2020 | $0.19 | $0.27 | 0.08 | $59.90 M | $65.32 M |
| 08/10/2020 | Q2 2020 | $0.25 | $0.19 | -0.06 | $66.68 M | $55.22 M |
| 05/11/2020 | Q1 2020 | -$0.02 | -$0.04 | -0.02 | $25.35 M | |
| 02/24/2020 | Q4 2019 | -$0.18 | -$0.24 | -0.06 | $53.67 M |
Halozyme Therapeutics, Inc. Earnings: Frequently Asked Questions
-
When is Halozyme Therapeutics, Inc.'s earnings date?
Halozyme Therapeutics, Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, February 18th, 2025 based off last year's report dates.
-
Did Halozyme Therapeutics, Inc. beat their earnings estimates last quarter?
In the previous quarter, Halozyme Therapeutics, Inc. (:HALO) reported $1.27 earnings per share (EPS) to beat the analysts' consensus estimate of $0.98 by $0.29.
-
How can I listen to Halozyme Therapeutics, Inc.'s earnings conference call?
The conference call for Halozyme Therapeutics, Inc.'s latest earnings report can be listened to online.
-
How can I read Halozyme Therapeutics, Inc.'s conference call transcript?
The conference call transcript for Halozyme Therapeutics, Inc.'s latest earnings report can be read online.
-
How much revenue does Halozyme Therapeutics, Inc. generate each year?
Halozyme Therapeutics, Inc. (:HALO) has a recorded annual revenue of $829.25 M.
-
How much profit does Halozyme Therapeutics, Inc. generate each year?
Halozyme Therapeutics, Inc. (:HALO) has a recorded net income of $829.25 M. Halozyme Therapeutics, Inc. has generated $2.13 earnings per share over the last four quarters.
-
What is Halozyme Therapeutics, Inc.'s price-to-earnings ratio?
Halozyme Therapeutics, Inc. (:HALO) has a price-to-earnings ratio of 18.73 and price/earnings-to-growth ratio is 1.07.
